Apr 08, 2013 (M2 PRESSWIRE via COMTEX) --
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Albany International Corp (NYSE:AIN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Copano Energy LLC (NASDAQ:CPNO), Penn National Gaming Inc (NASDAQ:PENN), Chelsea Therapeutics International Ltd (NASDAQ:CHTP), ZIOPHARM Oncology Inc (NASDAQ:ZIOP) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
The following stocks are expected to go Up:
Symbol Company Expected Return Odds By The Following Date
AIN Albany International Corp 8.84% 92.00% (23 of 25) Tuesday, April 30th 2013
RIGL Rigel Pharmaceuticals Inc 12.01% 91.67% (11 of 12) Friday, April 26th 2013
CPNO Copano Energy LLC 5.29% 100.00% (8 of 8) Tuesday, April 23rd 2013
PENN Penn National Gaming Inc 6.83% 92.31% (12 of 13) Friday, April 19th 2013
CHTP Chelsea Therapeutics International Ltd 12.76% 100.00% (7 of 7) Monday, May 6th 2013
ZIOP ZIOPHARM Oncology Inc 11.01% 85.71% (6 of 7) Wednesday, May 1st 2013
Albany International Corp (NYSE:AIN) - Albany International Corp. operates as a textiles and materials processing company worldwide. Its Machine Clothing segment designs, manufactures, and markets paper machine clothing and process belts used in the manufacture of paper and paperboard. This segment also offers forming, pressing, and dryer fabrics; consumable fabrics used to process paper pulp; belts used to make nonwovens, fiber cement building products, roofing shingles, and corrugated sheets used in boxboard; belts used in tannery and textile applications; and nonwovens, including diapers, personal care and household wipes, and fiberglass-reinforced roofing shingles. It sells its products directly to customer end-users, which include paper industry companies, nonwovens manufacturers, and building products companies. The company s Engineered Composites segment offers custom-designed composite structures based on proprietary technology to customers in commercial and military aircraft engine and airframe markets. Its PrimaLoft Products segment provides insulation materials for outdoor clothing, gloves, footwear, sleeping bags, and home furnishings. The company was founded in 1895 and is headquartered in Rochester, New Hampshire..
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) - Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that is in Phase III clinical trials for rheumatoid arthritis; R343, an inhaled SYK inhibitor, which completed Phase I clinical trials for asthma; R333, a topical JAK/SYK inhibitor, which is in Phase I clinical trials for the treatment of discoid lupus; and R548, an oral janus kinase 3 (JAK3) inhibitor that in Phase I clinical trials for the treatment of transplant rejection and other immune disorders. The company s research/preclinical programs comprise R348, a soluble JAK/SYK inhibitor for topical ophthalmic use; R256, an inhaled interleukin 13 signaling inhibitor for chronic asthma; an oral activator of adenosine monophosphate activated protein kinase for enhancing the body s energy utilization and restore muscle endurance in chronically ill subjects; and growth/differentiation factor 8 inhibitor to prevent muscle loss. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo Co., Ltd. to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California..
Copano Energy LLC (NASDAQ:CPNO) - Copano Energy, L.L.C. provides midstream services to natural gas producers in the United States. The company s services include natural gas gathering, compression, dehydration, treating, marketing, transportation, processing, and fractionation. It owns and operates natural gas gathering and intrastate transportation pipeline assets; natural gas processing and fractionation facilities; and natural gas liquid (NGL) pipelines in Texas, Oklahoma, Wyoming, and Louisiana. The company operates approximately 6,800 miles of natural gas gathering and transmission pipelines; and 10 natural gas processing plants with approximately 1 billion cubic feet per day of combined processing capacity. It also operates 380 miles of NGL pipelines. The company serves third-party pipelines, distribution companies, power generation facilities, and industrial customers. Copano Energy, L.L.C. was founded in 2001 and is based in Houston, Texas..
Penn National Gaming Inc (NASDAQ:PENN) - Penn National Gaming, Inc. owns and manages gaming and pari-mutuel properties in the United States and Canada. The company is involved in hotel, dining, retail, admissions, program sales, concessions, racing operations, and other ancillary activities. As of November 15, 2012, it operated 29 facilities in 19 jurisdictions, including Colorado, Florida, Illinois, Indiana, Iowa, Kansas, Louisiana, Maine, Maryland, Mississippi, Missouri, Nevada, New Jersey, New Mexico, Ohio, Pennsylvania, Texas, West Virginia, and Ontario. The company s operated facilities consist of approximately 36,800 gaming machines; approximately 850 table games; 2,900 hotel rooms; and approximately 1.6 million square feet of gaming floor space. The company was formerly known as PNRC Corp. and changed its name to Penn National Gaming, Inc. in May 1994. Penn National Gaming, Inc. was founded in 1972 and is based in Wyomissing, Pennsylvania..
Chelsea Therapeutics International Ltd (NASDAQ:CHTP) - Chelsea Therapeutics International, Ltd., a development-stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products. It is primarily developing Northera (droxidopa), a novel therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine- -hydroxylase, deficiency, and non-diabetic autonomic neuropathy. The company is also evaluating the therapeutic applications of droxidopa in reducing the frequency of falls in patients with Neurogenic OH associated with Parkinson s disease, as well as other potentially norepinephrine related conditions and diseases, including intradialytic hypotension, fibromyalgia, and adult attention deficit hyperactivity disorder. In addition, it engages in developing a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis and for the treatment of multiple other autoimmune disorders, including psoriasis, Crohn s disease, uveitis, ankylosing spondylitis, inflammatory bowel disease, cancer, and other immunological disorders. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina..
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) - ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of new cancer therapies. Its lead candidate, Palifosfamide (ZIO-201), a potent bi-functional DNA alkylating agent, is under Phase III trial for the treatment of first-line metastatic soft tissue sarcoma, as well as in a pivotal Phase III trial for first-line metastatic small cell lung cancer. The company s portfolio of clinical-stage product candidates also include IL-12 DNA, which is being tested in a Phase 2 study using synthetic biology to enable controlled, local delivery of therapeutic interleukin-12; Indibulin (ZIO-301), a novel, tubulin binding agent under Phase I/II trial in metastatic breast cancer; and Darinaparsin (ZIO-101), a novel mitochondrial- and hedgehog-targeted agent. In addition, its portfolio comprises various research-stage candidates. The company s DNA therapeutics are being developed in partnership with Intrexon Corporation through a synthetic biology platform that allows for targeted, controlled production of therapies in humans with a biologic on/off switch. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in New York, New York with operations center located in Boston, Massachusetts..
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Thomas Ronk, CEO
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to email@example.com.